UBT 251
Alternative Names: NN-9559; UBT-251Latest Information Update: 06 Mar 2026
At a glance
- Originator United Bio-Technology (Hengqin)
- Developer Novo Nordisk; United Bio-Technology (Hengqin)
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides; Urologics
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Obesity; Renal failure; Type 2 diabetes mellitus
Most Recent Events
- 24 Feb 2026 Efficacy and adverse event data from a phase II trial in Obesity released by Novo Nordisk
- 24 Feb 2026 Novo Nordisk plans a phase II trial for Type 2 diabetes mellitus, in the second half of 2026
- 24 Feb 2026 United Bio-technology completes enrolment in its phase II trial in Obesity in China (SC), prior to February 2026 (NCT07177469)